Editing BDPC

'''BDPC''' (systematic name '''4-(4-bromophenyl)-4-(dimethylamino)-1-(2-phenylethyl)cyclohexanol''') is a potent [[narcotic]] [[analgesic]] with a distinctive arylcyclohexylamine chemical structure. It was developed by the team led by Prof. Helmut Ortmanns and Dr. Juergen Sauer of the pharmaceutical company [[Grünenthal]] in the late 1970s and early 1980s.

==Chemistry==
BDPC is a [[cyclohexanol]] derivative and is structurally related to other drugs of the arylcyclohexylamine class, such as [[phencyclidine]] (PCP) and [[ketamine]]. It is specifically a 4-bromo derivative of 2-(2,6-dimethylphenylamino)-2-(2-phenylethyl)cyclohexan-1-one.

==Pharmacology==
BDPC acts as a [[mu-opioid receptor]] agonist. It is one of the most potent opioid agonists known, approximately 504 times more potent than [[morphine]] in animal models.

==Medical Use==
BDPC has never been used in humans, but would be expected to produce effects similar to those of other potent opioid agonists, including strong [[analgesia]], [[sedation]], [[euphoria]], [[constipation]], [[itching]] and [[respiratory depression]] which could be harmful or fatal.

==Legal Status==
BDPC is not currently listed in any schedule of the United Nations Drug Conventions, but it may be covered under the analogue act in some countries such as the United States or Australia.

==See Also==
* [[Opioid]]
* [[Analgesic]]
* [[Phencyclidine]]
* [[Ketamine]]

{{medicine-stub}}

[[Category:Opioids]]
[[Category:Analgesics]]
[[Category:Arylcyclohexylamines]]
[[Category:Mu-opioid agonists]]
<gallery>
File:Bromadol.svg|BDPC
File:Bromadol 3D BS.png|BDPC
File:4Methyl-bromadol structure.png|BDPC
File:4Chloro-bromadol structure.png|BDPC
File:3Hydroxy-bromadol structure.png|BDPC
</gallery>